EGFR and non-small cell lung carcinoma: One possible reason to explain the difference in 2-year DFS in stage IIIA NSCLC could be owing to understaging of patients in ADAURA by CT, whereas in our single-center study, 56 of 74 patients (75.7%) with EGFR-positive NSCLC underwent PET-CT staging.